TITLE

Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece

AUTHOR(S)
Anagnostopoulos, A.; Evangelopoulou, A.; Sotou, D.; Gika, D.; Mitsibounas, D.; Dimopoulos, M.-A.
PUB. DATE
July 2002
SOURCE
Annals of Hematology;Jun2002, Vol. 81 Issue 7, p357
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Monoclonal gammopathy of undetermined significance (MGUS) is a relatively common condition among individuals older than 70 years. The actuarial risk of MGUS progression to an overt plasma cell malignancy (PCM) after 20 years of follow-up has been reported to be as high as 30%. The purpose of this study was to evaluate the incidence and evolution of MGUS in a Greek population: 1564 consecutive patients older than 50 years who were admitted to the Department of Clinical Therapeutics at the University of Athens School of Medicine for various reasons over a 26-month period were evaluated with serum protein electrophoresis. In cases in which a monoclonal protein was detected, a panel of tests was performed to rule out an underlying plasma cell malignancy (PCM). Serum levels of interleukin (IL)-6, IL-6-soluble receptor (IL-6SR), IL-1 beta, and transforming growth factor beta 1 were also measured in the MGUS cases. Patients with MGUS were monitored at regular intervals for evidence of multiple myeloma or other PCMs. The incidence of MGUS was 4% and there was a positive correlation with increasing age. The median value of serum M peak was only 5.3 g/l. After a median follow-up of 71 months, only two patients developed multiple myeloma (60 and 75 months after initial diagnosis). Our data are consistent with those of other epidemiological studies regarding the incidence of MGUS, but the monoclonal protein levels and the probability of evolution to a malignant plasma cell disorder appeared to be lower in our study than in other series. Our data support the hypothesis that individuals with low M peak values require only regular annual follow-up examinations.
ACCESSION #
15684947

 

Related Articles

  • The Pancreas and Immunoglobulins 1. Immunoglobulin Levels in Pancreatic Secretion of Patients with Normal Function: Preliminary Studies. Soto, Julio M.; Bramis, John; Aufses Jr., Arthur; Dreiling, David A. // American Journal of Gastroenterology;Apr1977, Vol. 67 Issue 4, p345 

    Presents a study which analyzed the immunoglobulin levels in pancreatic secretion of patients with normal function. Methods used in the study; Findings of the study; Explanation on the wide range of immunoglobulin levels in normal patients.

  • Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders. Vellas, Bruno; Black, R.; Thal, Leon J.; Fox, Nick C.; Daniels, M.; McLennan, G.; Tompkins, C.; Leibman, C.; Pomfret, M.; Grundman, Michael // Current Alzheimer Research;Apr2009, Vol. 6 Issue 2, p144 

    Background: Immunization of patients with Alzheimer's disease (AD) with synthetic amyloid-β peptide (Aβ42) (AN1792) was previously studied in a randomized, double-blind, placebo-controlled phase 2a clinical trial, Study AN1792(QS-21)-201. Treatment was discontinued following reports of...

  • Stabilisation of Laryngeal AL Amyloidosis with Long Term Curcumin Therapy. Golombick, Terry; Diamond, Terrence H.; Manoharan, Arumugam; Ramakrishna, Rajeev // Case Reports in Hematology;6/25/2015, Vol. 2015, p1 

    Multiple myeloma (MM), smoldering myeloma (SMM), and monoclonal gammopathy of undetermined significance (MGUS) represent a spectrum of plasma cell dyscrasias (PCDs). Immunoglobulin light chain amyloidosis (AL) falls within the spectrum of these diseases and has a mortality rate of more than 80%...

  • Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cortes, Jorge; Tsimberidou, Apostolia M.; Alvarez, Ricardo; Thomas, Deborah; Beran, Miloslav; Kantarjian, Hagop; Estey, Elihu; Giles, Francis J. // Cancer Chemotherapy & Pharmacology;Dec2002, Vol. 50 Issue 6, p497 

    Purpose: Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with...

  • Undiagnosed hepatitis C virus infection in hemodialysis patients: Value of HCV RNA and liver enzyme levels. Caramelo, Carlos; Bartolomé, Javier; Albalate, Marta; de Sequera, Patricia; Navas, Sonia; Bermejillo, Teresa; Oliva, Horacio; Marriott, Eduardo; Ortiz, Alberto; Tuñón, Carmen Ruiz; Casado, Santos; Carreño, Vicente // Kidney International;Dec1996, Vol. 50 Issue 6, p2027 

    At present, routine screening for hepatitis C virus (HCV) infection is based on the detection of antiviral antibodies. Underdiagnosis of HCV infection by using HCV antibody tests, however, still occurs. Additional diagnostic means are provided by the polymerase chain reaction (PCR). The...

  • Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. De Vos, John; Thykjaer, Thomas; Rarte, Karin; Ensslen, Matthias; Raynaud, Pierre; Requirand, Guilhem; Pellet, Florence; Pantesco, Veronique; Reme, Thierry; Jourdan, Michael; Rossi, Jean-Francois; Orntoft, Torben; Klein, Bernard // Oncogene;10/3/2002, Vol. 21 Issue 44, p6848 

    Provides information on a study that compared the gene expression profiles of highly purified malignant plasma cells from patients with multiple myeloma and several myeloma cell lines those of highly purified nonmalignant plasma cells obtained by in vitro differentiation of peripheral blood B...

  • End game for B cells. Calame, Kathryn // Nature;7/19/2001, Vol. 412 Issue 6844, p289 

    Reports on the discovery of a protein called XBP-1, which is considered essential to the development of plasma cells that secrete antibodies. Strategic defense of the body against foreign invaders; Description of how XBP-1 functions; Implications of the discovery to immunology.

  • Intracellular Antibodies as Specific Reagents for Functional Ablation: Future Therapeutic Molecules. Lobato, M. N.; Rabbitts, T. H. // Current Molecular Medicine;Aug2004, Vol. 4 Issue 5, p519 

    The use of antibodies in medicine and research depends on their specificity and affinity in the recogniton and binding of individual molecules. However, these applications are limited to the extracellular targets. Advances in antibody engineering has allowed the manipulation of the antibody...

  • Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Seckinger, A; Meißner, T; Moreaux, J; Goldschmidt, H; Fuhler, G M; Benner, A; Hundemer, M; Rème, T; Shaughnessy, J D; Barlogie, B; Bertsch, U; Hillengass, J; Ho, A D; Pantesco, V; Jauch, A; De Vos, J; Rossi, J F; Möhler, T; Klein, B; Hose, D // Oncogene;11/5/2009, Vol. 28 Issue 44, p3866 

    Pathogenesis of multiple myeloma is associated with an aberrant expression of pro-proliferative, pro-angiogenic and bone-metabolism-modifying factors by malignant plasma cells. Given the frequently long time span from diagnosis of early-stage plasma cell dyscrasias to overt myeloma and the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics